Citations

Clear

3138 citation(s) found for "Smith, AM".

Quantitative phenotype analysis to identify, validate and compare rat disease models
Zhao, Yiqing , Smith, Jennifer R. , Wang, Shur‐Jen , Dwinell, Melinda R. , Shimoyama, Mary

Mayo Clinic

Database | March 5, 2019 | Volume: 2019 | Issue: No issue available | Pages: No page available

10.1093/database/baz037 | PMID 30938777 Get It

NKAP Must Associate with HDAC3 to Regulate Hematopoietic Stem Cell Maintenance and Survival
Shapiro, Michael J. , Lehrke, Michael Jonathan , Chung, Ji Young, Arocha, Sinibaldo Romero , Shapiro, Virginia Smith , Shapiro, Michael Jeremy , Romero Arocha, Sinibaldo, Shapiro, Virginia S , Lehrke, Michael J

Mayo Clinic

The Journal of Immunology | February 25, 2019 | Volume: 202 | Issue: 8 | Pages: 2287-2295

10.4049/jimmunol.1800862 | PMID 30804042 Get It

Abstract NKAP is a multifunctional nuclear protein that associates with the histone deacetylase HDAC3. Although both NKAP and HDAC3 are critical for hematopoietic stem cell (HSC) maintenance and survival, it was not known whether these two proteins work together. To assess the importance of their association in vivo, serial truncation and alanine scanning was performed on NKAP to identify the minimal binding site for HDAC3. Mutation of either Y352 or F347 to alanine abrogated the association of NKAP with HDAC3, but did not alter NKAP localization or expression. Using a linked conditional deletion/re-expression system in vivo, we demonstrated that re-expression of the Y352A NKAP mutant failed to restore HSC maintenance and survival in mice when endogenous NKAP expression was eliminated using Mx1-cre and poly-IC, whereas re-expression of wild type NKAP maintained the HSC pool. However, Y352A NKAP did restore proliferation in murine embryonic fibroblasts when endogenous NKAP expression was eliminated using ER-cre and tamoxifen. Therefore, Y352 in NKAP is critical for association with HDAC3 and for HSC maintenance and survival but is not important for proliferation of murine embryonic fibroblasts, demonstrating that NKAP functions in different complexes in different cell types.
Breast Cancer, Version 3.2018
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Farrar, William B., Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Moran, Meena S. , O'Regan, Ruth M., Patel, Sameer A. , Pierce, Lori J. , Reed, Elizabeth , Sitapati, Amy M. , Smith, Mary Lou , Telli, Melinda L. , Shead, Dorothy A. , Goetz, Matthew P. , Elias, Anthony , Giordano, Sharon H. , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 118-126

10.6004/jnccn.2019.0009 | PMID 30787125 Get It

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
Effect of Lidocaine on Viability and Gene Expression of Human Adipose–derived Mesenchymal Stem Cells: An in vitro Study
Nie, Hai , Kubrova, Eva , Denbeigh, Janet M. , Dietz, Allan B. , Smith, Jay , Qu, Wenchun , Wijnen, André J. van , Hunt, Christine , van Wijnen, Andre J , Dietz, Allan B , Wu, Tao , Hunt, Christine

Mayo Clinic

PM&R | February 20, 2019 | Volume: 11 | Issue: 11 | Pages: 1218-1227

10.1002/pmrj.12141 | PMID 30784215 Get It

ObjectiveTo assess the biologic effects of lidocaine on the viability, proliferation, and function of human adipose tissue–derived mesenchymal stromal/stem cells (MSCs) in vitro.MethodsAdipose‐derived MSCs from three donors were exposed to lidocaine at various dilutions (2 mg/mL to 8 mg/mL) and exposure times (0.5 to 4 hours). Cell number and viability, mitochondrial activity, and real‐time reverse‐transcriptase quantitative polymerase chain reaction (RT‐qPCR) were analyzed at 0 (immediate effects) or 24 and 48 hours (recovery effects) after treatment with lidocaine.ResultsTrypan blue staining showed that increasing concentrations of lidocaine decreased the number of observable viable cells. 3‐[4,5,dimethylthiazol‐2‐yl]‐5‐[3‐carboxymethoxy‐phenyl]‐2‐[4‐sulfophenyl]‐2H‐tetrazolium (MTS) assays revealed a concentration‐ and time‐ dependent decline of mitochondrial activity and proliferative ability. Gene expression analysis by RT‐qPCR revealed that adipose‐derived MSCs exposed to lidocaine express robust levels of stress response/cytoprotective genes. However, higher concentrations of lidocaine caused a significant downregulation of these genes. No significant differences were observed in expression of extracellular matrix (ECM) markers COL1A1 and DCN except for COL3A1 (P < .05). Levels of messenger RNA (mRNA) for proliferation markers (CCNB2, HIST2H4A, P < .001) and MKI67 (P < .001) increased at 24 and 48 hours. Expression levels of several transcription factors— including SP1, PRRX1, and ATF1—were modulated in the same manner. MSC surface markers CD44 and CD105 demonstrated decreased expression immediately after treatment, but at 24 and 48 hours postexposure, the MSC markers showed no significant difference among groups.ConclusionLidocaine is toxic to MSCs in a dose‐ and time‐ dependent manner. MSC exposure to high (4‐8 mg/mL) concentrations of lidocaine for prolonged periods can affect their biologic functions. Although the exposure time in vivo is short, it is essential to choose safe concentrations when applying lidocaine along with MSCs to avoid compromising the viability and potency of the stem cell therapy.
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Mossé, Yaël P. , Fox, Elizabeth , Hall, David , Safgren, Stephanie L. , Carol, Hernán, Lock, Richard B. , Houghton, Peter J. , Smith, Malcolm A. , Barkauskas, Donald A. , Krailo, Mark , Voss, Stephan D. , Blaney, Susan M. , Weigel, Brenda J. , Teachey, David T. , Teachey, David T , Reid, Joel M. , Smith, Malcolm A , Berg, Stacey L , Safgren, Stephanie L , Berg, Stacey L.

Mayo Clinic

Clinical Cancer Research | February 18, 2019 | Volume: 25 | Issue: 11 | Pages: 3229-3238

10.1158/1078-0432.ccr-18-2675 | PMID 30777875 Get It

Abstract Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.
The early proximal αβ TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network
Neier, Steven C. , Ferrer, Alejandro , Wilton, Katelynn M. , Smith, Stephen , Kelcher, April M. Huseby , Pavelko, Kevin D. , Canfield, Jenna M. , Davis, Tessa R. , Stiles, Robert J. , Chen, Zhenjun , McCluskey, James , Rossjohn, Jamie , Hebrink, Deanne, Carmona, Eva M. , Kappes, Dietmar J. , Wettstein, Peter J., Johnson, Aaron J. , Pease, Larry R. , Neuhauser, Claudia , Gil, Diana , Schrum, Adam G. , Smith, Stephen E P , Kelcher, April M H , Rossjohn, Jamie , Hebrink, Deanne M, Johnson, Aaron J. , Daniels, Mark A , Neuhauser, Claudia , Gil, Diana , Schrum, Adam G , Carmona, Eva M , Pavelko, Kevin D , Canfield, Jenna M , Burrows, Scott R. , Limper, Andrew H. , Daniëls, Mark A. , Ferrer, Alejandro

Mayo Clinic

Science Immunology | February 16, 2019 | Volume: 4 | Issue: 32 | Pages: No page available

10.1126/sciimmunol.aal2201 | PMID 30770409 Get It

Quantitative activity through the TCR-proximal protein network specifies thymic positive versus negative selection.
Longitudinal analysis of epigenome-wide DNA methylation reveals novel smoking-related loci in African Americans
Liu, Jiaxuan , Zhao, Wei , Ammous, Farah , Mosley, Thomas H. , Zhou, Xiang , Smith, Jennifer A. , Zhao, Wei , Turner, Stephen T. , Zhou, Xiang , Smith, Jennifer A , Zhao, Wei

Mayo Clinic

Epigenetics | February 15, 2019 | Volume: 14 | Issue: 2 | Pages: 171-184

10.1080/15592294.2019.1581589 | PMID 30764717 Get It

De novo DDX3X missense variants in males appear viable and contribute to syndromic intellectual disability
Nicola, Pantelis , Blackburn, Patrick R. , Rasmussen, Kristen , Bertsch, Nicole L. , Klee, Eric W. , Hasadsri, Linda , Pichurin, Pavel N. , Rankin, Julia, Raymond, F. Lucy , Study, DDD, Clayton‐Smith, Jill, Rasmussen, Kristen J , Study, DDD, Clayton‐Smith, Jill

Mayo Clinic

American Journal of Medical Genetics Part A | February 8, 2019 | Volume: 179 | Issue: 4 | Pages: 570-578

10.1002/ajmg.a.61061 | PMID 30734472 Get It

DDX3X (Xp11.4) encodes a DEAD‐box RNA helicase that escapes X chromosome inactivation. Pathogenic variants in DDX3X have been shown to cause X‐linked intellectual disability (ID) (MRX102, MIM: 300958). The phenotypes associated with DDX3X variants are heterogeneous and include brain and behavioral abnormalities, microcephaly, hypotonia, and movement disorders and/or spasticity. The majority of DDX3X variants described are de novo mutations in females with ID. In contrast, most male DDX3X variants are inherited from an unaffected mother, with one documented exception being a recently identified de novo splice site variant. It has been suggested, therefore, that DDX3X exerts its effects through haploinsufficiency in females, and that affected males carry hypomorphic alleles that retain partial function. Given the lack of male de novo DDX3X variants, loss‐of‐function variants in this gene are suspected to be male lethal. Through whole‐exome sequencing, we identified three unrelated males with hemizygous missense DDX3X variants and ID. All three variants were confirmed by Sanger sequencing, with two established as de novo. In silico analyses were supportive of pathogenicity. We report the male phenotypes and compare them to phenotypes observed in previously reported male and female patients. In conclusion, we propose that de novo DDX3X variants are not necessarily male lethal and should be considered as a cause of syndromic ID in both males and females.
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Bartlett, Nancy L. , Smith, Sonali M. , Leonard, John P. , Evens, Andrew M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Hsi, Eric D. , Li, Hongli , Nixon, Andrew B. , Schöder, Heiko , LeBlanc, Michael , Kahl, Brad S. , Scott, David W. , Rimsza, Lisa M.

Mayo Clinic

Blood | February 6, 2019 | Volume: 133 | Issue: 16 | Pages: 1762-1765

10.1182/blood-2018-08-870915 | PMID 30723079 Get It

Abstract Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)–positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.